Enfortumab vedotin aneb začátek cesty k vyléčení pokročilého uroteliálního karcinomu?!

doc. MUDr. Hana Študentová, Ph.D.

Onkologie. 2024:18(Suppl.C):4-5

Enfortumab vedotin in the treatment of generalized urothelial carcinoma of the renal pelvis and ureter

Eva Kindlová, Jan Dvořák

Onkologie. 2024:18(Suppl.C):6-12 | DOI: 10.36290/xon.2024.044

Antibody-drug conjugates are gradually being incorporated into recommended treatment protocols for various cancer diagnoses, primarily breast cancer and haematological malignancies. However, in patients with generalized urothelial carcinoma who have been pretreated with chemotherapy and immunotherapy, a drug of this type - enfortumab vedotin - is also indicated and now reimbursed in the Czech Republic. Our case report documents the potential benefit of this drug in the treatment of urothelial carcinoma of the renal pelvis and ureter.

The early experiences with enfortumab vedotin in patients with metastatic bladder cancer

Jindřich Kopecký

Onkologie. 2024:18(Suppl.C):13-20 | DOI: 10.36290/xon.2024.045

Enfortumab vedotin is an innovative targeted therapy for the treatment of metastatic urothelial carcinoma, demonstrating efficacy but also presenting certain toxicity risks. The following case report presents two distinct cases along with the adverse effects induced by this treatment. These two cases underscore the necessity for careful monitoring and management of these adverse effects. These experiences highlight the need to balance the effectiveness and safety of enfortumab vedotin treatment, where despite its high thera­peutic potential, an individualized approach must be taken considering potential toxicity.

Padcev (enfortumab vedotin): a new treatment option for urothelial carcinoma

Lenka Ostřížková

Onkologie. 2024:18(Suppl.C):21-24 | DOI: 10.36290/xon.2024.046

The case report presents the initial clinical experience from routine practice with the Padcev (enfortumab vedotin) agent in treating metastatic urothelial carcinoma after failure of a platinum derivative and PD-1/PD-L1 inhibitor.

Enfortumab vedotin in the treatment of urothelial bladder carcinoma

Kateřina Pejřová, Anežka Zemánková

Onkologie. 2024:18(Suppl.C):25-30 | DOI: 10.36290/xon.2024.047

The case report describes the case of a 67-year-old woman with metastatic urothelial carcinoma. For the first-line chemotherapy carboplatin/gemcitabine regimen was chosen. Due to a partial response, the maintenance treatment with avelumab was subsequently continued, but the disease relapsed after 3 months of the therapy. According to the current standard of treatment of urothelial bladder carcinoma, the patient started the second-line treatment with enfortumab vedotin. A partial response was achieved after 3 months of the therapy with enfortumab vedotin and the patient benefited from the treatment for a total of 8 months.

Effect of treatment with enfortumab vedotin in a patient with generalized urothelial carcinoma pretreated with platinum and avelumab

Šárka Stuhlová

Onkologie. 2024:18(Suppl.C):31-35 | DOI: 10.36290/xon.2024.048

Superficial bladder cancer is a disease with an excellent prognosis. By contrast, patients with a locally advanced or metastatic disease have a very low chance for long-term survival. For a number of years, platinum-based chemotherapy has been the gold standard of treatment, with an expected survival of less than two years. It was only with the introduction of immunotherapy with checkpoint inhibitors that long-term treatment responses were observed in a proportion of patients and, along with that, increased chances for longer-term survival. More recently, enfortumab vedotin (Padcev), which expands the armamentarium of treatment options for advanced...